In the news release, Ambetter from Peach State Health Plan Offers Health Insurance in Georgia in 2026, issued 03-Nov-2025 by Peach State Health Plan over PR Newswire, we are advised by the company that disclaimers should have been included at the end of the release, with asterisks added for reference in the fifth and sixth bullets. The complete, corrected release follows:
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from Peach State Health Plan plans in 149 counties
ATLANTA, Nov. 3, 2025 /PRNewswire/ -- Ambetter from Peach State Health Plan, a product offered by a Centene Corporation (NYSE: CNC) company, a leading healthcare enterprise that provides insurance to under-insured and uninsured populations through the Health Insurance Marketplace®, will offer a variety of affordable health insurance plans to Georgians in 149 counties for plan year 2026. The open enrollment period for the Health Insurance Marketplace runs from Nov. 1, 2025, through Jan. 15, 2026. Enroll by Dec. 15, 2025, for coverage starting Jan. 1, 2026.
"Our mission is to ensure that every Georgian can choose healthcare coverage that fits their needs and supports their health journey," said Plan President and Chief Executive Officer of Peach State Health Plan, Clyde White. "With enhanced benefits, innovative solutions and tools for enrollment and care, we're making it easier for individuals and families to take control of their health."
Ambetter from Peach State Health Plan offers its members access to quality care and convenient services. 2026 benefits and offerings include:
The full list of 149 counties in which Ambetter from Peach State Health Plan will be offered can be found at ambetterhealth.com/en/ga/health-plans/coverage-map.
Georgia residents interested in learning more about Ambetter from Peach State Health Plan or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ga.
About Ambetter from Peach State Health Plan
Ambetter from Peach State Health Plan serves under-insured and uninsured populations through Georgia Access. Ambetter from Peach State Health Plan is underwritten by Ambetter of Peach State, Inc., which is a Qualified Health Plan issuer in Georgia. Ambetter Health, offering the Ambetter Health Solutions product, is underwritten by Peach State Health Plan, Inc. For more information, visit ambetterhealth.com/en/ga/. This is a solicitation for insurance. For information on your right to receive an Ambetter from Peach State Health Plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
*Healthcare-related costs will vary by member and the plan in which you are enrolled. Funds expire immediately upon termination of insurance coverage. My Health Pays® rewards cannot be used for pharmacy copays. Restrictions apply. Members must qualify for and complete all activities to receive $500 or more. Visit Member.AmbetterHealth.com for more details. Your health plan is committed to helping you achieve your best health. Rewards for participating in a wellness program are available to all members. If you think you might be unable to meet a standard for a reward under this wellness program, you might qualify for an opportunity to earn the same reward by different means.
**Cost sharing may apply when using Virtual 24/7 Care or Virtual Primary Care. Virtual 24/7 Care cost share does not apply to HSA plans until the deductible is met and is only applicable when used through the Virtual 24/7 Care program. Ambetter Health does not provide medical care. Medical care is provided by individual providers, which are independent contractors and not agents of Ambetter Health.

| Last Trade: | US$34.50 | 
| Daily Change: | -0.87 -2.46 | 
| Daily Volume: | 8,793,506 | 
| Market Cap: | US$16.960B | 
 October 29, 2025  July 29, 2025  July 25, 2025  April 25, 2025  | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load